Abstract Melanoma represents the most aggressive form of skin cancer, and its incidence continues to rise worldwide.
Introduction
Although melanoma constitutes a small percentage of all skin cancer cases, it accounted for an estimated 76,380 new cases and 10,130 deaths in the United States in 2016 [1] . Unsatisfactory 5-year survival rates of less than 10% for patients with distant metastases render early detection and accurate assessment of metastatic melanoma crucial for improved outcome and disease-free survival [2] . As our understanding of the molecular pathogenesis of melanoma has gradually improved over the past 10 years, the treatment landscape for advanced melanoma has been dramatically transformed. Novel agents such as molecularly targeted therapies specifically inhibiting carcinogenic pathways and immunotherapies augmenting antitumor activity have emerged as new standards of care for patients with melanoma [3] .
A s e l e g a n t l y r e v i e w e d b y Wo n g e t a l . , 1 8 Ffluorodeoxyglucose (FDG) positron emission tomography (PET) can play a pivotal role in the interpretation of therapeutic response following BRAF inhibition and immunotherapy in patients with melanoma, facilitating early assessment of drug resistance and detection of life-threatening autoimmune side effects [4] . 18 F-FDG PET was also recommended for staging Weijun Wei and Emily B. Ehlerding contributed equally to this work and detecting recurrent melanoma [5, 6] . However, because 18 F-FDG PET monitors cellular metabolism, and immunotherapy elicits a natural inflammatory response, traditional PET imaging using 18 F-FDG has proven inadequate in examining responses to immunotherapy in certain cancer types [7] . Moreover, owing to increased glucose metabolism in inflammatory tissues, 18 F-FDG displays relatively poor selectivity for distinguishing tumor from inflammatory tissue. Importantly, in one study, 18 F-FDG PET failed to detect melanoma in patients showing a positive sentinel lymph node biopsy for cancer, and no melanoma recurrence was observed in cases where the 18 F-FDG PET scans were positive or suspicious [8] . 18 F-FDG PET scans also failed to detect pulmonary and brain metastases, indicating its limited value for staging of patients with more advanced melanoma [9] . Currently, gadolinium-enhanced magnetic resonance imaging (MRI) is the most sensitive and reproducible method available for measuring brain metastases or assessing treatment response [10, 11] .
In an era of precision medicine and molecular imaging [12] , many radiolabeled probes designed for imaging of various molecular targets or biochemical processes have been developed and evaluated for melanoma imaging. Although clinically available 111 In-DOTA-lanreotide and 111 In-DOTA-Tyr3-octreotide can be used for melanoma imaging, the detection rates may not meet clinical requirements, and their mechanisms remain unknown [13] . In the past, we and others have conducted reviews regarding anatomical and molecular imaging of skin cancer [14, 15] ; since then, a substantial number of molecular imaging probes for melanoma have been developed. Although nanoparticle-based multimodal imaging systems have been extensively applied to melanoma detection and therapy, it is beyond the scope of the current paper. Therefore, with an emphasis on the small moleculeand peptide-based PET imaging probes, we aim to systematically review the recent advances in the field and offer an outlook on future development. Given the multidisciplinary nature of this field, our present review is by no means exhaustive, but we intend to summarize the most recent advances, allowing scientists to further refine these probes and clinicians to promote the clinical transition of those which appear promising, facilitating better management of patients with melanoma in the near future.
Small molecule-based probes targeting melanin
Melanin, an amorphous, irregular, functional biopolymer and a ubiquitous natural pigment in many organs including human skin, is a source of novel research opportunities in the fields of biomedicine, nanotechnology, and materials science [16] . In malignant melanoma, melanin formation is markedly increased because of significantly elevated tyrosinase activity [17, 18] , making it a very attractive theranostic target. Many drugs, including methylene blue (MTB), chloroquine, acridine orange, benzamide (BZA) and its analogs, and other aromatic compounds, have been found to bind to melanin both in vivo and in vitro [19] [20] [21] [22] [23] [24] . Melanin-targeting prodrugs also have been developed and used for in vivo melanoma imaging [25, 26] .
Radiolabeled benzamide and benzamide derivatives
Various versions of radiolabeled benzamide and its analogs have been developed for targeting of melanin in clinical practice [27] [28] [29] [30] [31] [32] [33] . Specifically, as evidenced by a recent prospective and multicenter phase III clinical study, 123 I-BZA 2 (Fig. 1a) [30, 34] , a benzamide derivative able to bind to melanin pigment in melanoma cells, demonstrated statistically higher specificity than 18 F-FDG for diagnosis of melanoma metastases in lesion-based analysis [39] . Katsifis and co-authors substituted the benzamide moiety with a nicotinamide moiety and labeled the compound with no-carrier-added 123 I-iodine via iododestannylation reactions. Biodistribution showed that 66% of the injected 123 I-1 ( 123 I-MEL008; Fig. 1b ) was excreted from the urinary system at 1 h post-injection, also displaying the highest tumor uptake at that time point, mainly because of its enhanced hydrophilicity and rapid clearance via renal excretion [35] . Chezal et al. then examined the biological properties of aromatic or heteroaromatic BZA analogs in B16 melanoma-bearing mice and found that melanin-specific binding compound ICF01012, when labeled with 131 I or 125 I, could be applied in radionuclide diagnosis and treatment of disseminated melanoma [20, [40] [41] [42] . The authors also developed a new multimodal approach by designing iodinated and fluorinated analogs of ICF01012, among which 18 F-8 emerged as the most promising compound, demonstrating high tumor uptake, high contrast, and rapid clearance [43] . These efforts also led to the development of 123 I-MEL037 and 123 I-53 ( Fig. 1c, d) ; while the former demonstrated high and prolonged tumor uptake, the latter, which was derived through structural modification of 123 I-MEL037, performed even better than 123 I-ICF01012, with tumor-to-background uptake ratios for 123 I-53 and 123 I-ICF01012 of 31.9 and 18.5, respectively [36, 37] . Although the above-described probes accumulated at high levels in the eyes and thyroid, radioiodinated iochlonicotinamide and radioiodinated phenylacetamides ( 131 I-IHPA and 131 I-IHPP) had lower uptake in most normal organs and highly specific uptake in the melanotic tumor (Fig. 1e, f) [38, 44] . After 18 F-FBZA was found to exhibit high tumor uptake, emerging as a promising candidate for clinical study (Fig. 2a ) [45] , Wu et al. modified the phenol moiety of benzamide with a short-chain polyethylene glycol (PEG) and then labeled with 18 to distinguish tumor from inflammatory tissue, as turpentineinduced inflammation revealed low radioactivity accumulation [46] . Garg and co-authors developed 4-11 C-MBZA and reported that this probe displayed advantages over its 18 F analogs, while delivering a lower dose of radiation to the subject (Fig. 2c) . In vitro binding studies showed specific binding of [4] [5] [6] [7] [8] [9] [10] [11] C-MBZA to B16/F1 cells; however, it also accumulated to a high level in the kidneys [47] . Chang et al. developed 18 F-NOTA-BZA, which demonstrated melanin-specific binding ability, low bone uptake, sustained tumor retention, high hydrophilicity (log P = −1.96), fast normal tissue clearance, and low radiation burden, indicating its promise as a PET probe for melaninspecific imaging of melanin-positive melanoma [53] . Based on highly encouraging preclinical results for 18 F-MEL050 [45] [46] [47] [48] [49] [50] [51] [52] ( Fig. 2d) [48, 54] , Liu et al. successfully synthesized a series of 18 F-MEL050 analogs for melanoma imaging (Fig. 2e, f) , of which 18 F-2 showed superior tumor-targeting efficacy and imaging properties [49] . Interestingly, recent research has proposed that N-(2-diethylaminoethyl) rather than the aromatic ring structure in benzamide analogs is a plausible pharmacophore responsible for melanin targeting, as the synthesized probe 18 F-FPDA exhibited relatively high B16/F10 tumor-targeting efficacy and favorable in vivo pharmacokinetics (Fig. 2g) [50] .
In addition to the most commonly used PET radionuclides, 68 Ga (t 1/2 = 68 min) is an outstanding radioisotope for molecular imaging due to its significant 89% positron yield and its availability without the establishment of expensive cyclotron and synthesis models [55] . Trencsényi et al. conjugated procainamide (PCA) with two different chelators, HBED-CC and NODAGA, and then labeled the compounds using Ga-68 and investigated the diagnostic value of 68 Ga-HBED-CC-PCA and 68 Ga-NODAGA-PCA in vitro and in vivo. The authors found that uptake of 68 Ga-NODAGA-PCA by melanin-containing melanoma was significantly higher than the accumulation of the 68 Ga-HBED-CC-conjugated PCA [56, 57] .
Imaging of melanoma metastases
Given that the presence of distant metastases, especially brain metastases, is associated with worse prognosis for patients with melanoma, early detection is critical [58] . In a study comparing the diagnostic value of 18 F-FDG PET/CT and MRI in melanoma patients with palpable lymph node metastases, Aukema et al. found that 18 F-FDG PET/CT changed the intended regional node dissection in 26 patients (37%) and demonstrated superior diagnostic accuracy of 93%, but missed five patients with brain metastases which were detected by MRI [59] . Similarly, another study showed that 18 F-FDG PET failed to detect metastatic lesions of less than 1 cm located in the lung, liver, or brain [60] . Currently, contrast-enhanced MRI and 18 F-FET PET appear to be the only reliable methods for detecting brain metastases from melanoma, but they still lack specificity [10, 61] . Moreover, in patients with surgically treatable IIIC and IV metastatic melanoma following targeted/immunotherapy, PET/CT was found to detect unexpected metastases that were missed with conventional imaging, and can be considered as part of preoperative workup [4, 62, 63] . This underscores the importance of developing novel radiotracers capable of identifying occult lesions or distant small metastases from melanoma with high specificity and low false-positive rates. Notably, the ability of an imaging agent to cross the blood-brain barrier (BBB) is considered critical in effective targeting of metastatic lesions in the brain. Of the reported probes, 4-11 C-MBZA was able to cross the BBB, and the corresponding uptake was moderate in the normal brain [47] . As observed from biodistribution and PET studies, 4-11 C-MBZA uptake in normal tissues was notably lower than that for several other 18 (Fig. 2h) , may be more effective than 18 F-FDG PET/CT for the delineation of small lymph node and lung metastases from melanoma [45, 46, 51, [65] [66] [67] .
18 F-5-FPN, a probe identical to 18 F-2, successfully detected pigmented B16/F10 tumors as early as 1 min after injection of the tracer. The uptake increased over time, and the tracer was rapidly excreted via the kidneys. This and subsequent studies from the same group further validated the potential of 18 F-5-FPN PET for the early detection of metastatic melanoma lesions (Fig. 2i) [52, 65] . 18 F-MEL050 exhibited excellent retention in melanincontaining tumors and rapid background clearance [48] . It should be noted, however, that the route of administration of 18 F-MEL050 is an important consideration for imaging of regional lymph node metastasis from melanoma. In a study using a mouse model, while 18 F-MEL050 PET correctly identified 100% of the lymph node metastases after subcutaneous administration of the tracer, only 60% of those metastases were found after systemic administration of the tracer in the lateral tail vein [54] .
Peptide-based imaging probes
Peptides are emerging as potent and selective ligands that can be designed to bind with high affinity and specificity to cell surface receptors on a wide range of tumors [68] . Three major types of peptides-α-melanocyte-stimulating hormone (α-MSH), tumor angiogenesis-associated integrins, and peptides targeting both the melanocortin 1 receptor (MC1R) and integrin-are under intensive development for molecular imaging of melanoma.
α-Melanocyte-stimulating hormone (α-MSH)-based probes
α-MSH, a ligand specific for MC1R, has been reported to be over-expressed in both melanotic and amelanotic human melanoma cases, and has been widely used as a vehicle for melanoma-targeted imaging and therapy [69] [70] [71] [72] [73] . As native α-MSH (a linear 13-amino acid peptide, Ac-SerTyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH 2 ) has a biological half-life of less than 3 min in vivo [74] , tremendous work has been undertaken over the past 20 years in an effort to add biological stability and improve targeting, and several modified analogs and synthesis strategies have been developed. For example, substitution of Met 4 with Nle 4 and Phe 7 with D-Phe 7 yields NDP-α-MSH [75] . In the decades since 6 -Phe 7 -Arg 8 -Trp 9 was identified as the Bessential core^of the native α-MSH peptide [76] , both linear and transition-metal rhenium-cyclized α-MSH have been constructed, including NAPamide [77] , DOTA-NAPamide [78] , ReCCMSH [77] , MTII [79] , analogs of MTII [80] , DOTACycMSH and DOTA-GlyGlu-CycMSH [81] , and DOTANle-CycMSH hex [82] . New highly specific and selective ligands against MC1R for melanomas have also recently been developed and have been explored as platforms for molecular imaging of melanoma [83, 84] .
Using the previously synthesized ReCCMSH, which has nanomolar affinity for MC1R, McQuade et al. labeled the peptide with PET isotopes 64 Cu and 86 Y, and assessed their diagnostic efficacy in melanoma tumors. Biodistribution studies revealed that the tumor concentration of 86 Y-DOTAReCCMSH and 64 Cu-DOTA-ReCCMSH was twice as high as that of the metabolic agent 18 F-FDG [85] . Additionally, the use of the chelator CBTE2A provided improved stability, as uptake of 64 Cu-CBTE2A-ReCCMSH was significantly lower than that for 64 Cu-DOTA-ReCCMSH in normal organs including the liver, lung, heart, and spleen [86] . Wei et al. then successfully labeled DOTA-ReCCMSH (Arg 11 ) with 68 Ga, and reported that the tumor uptake of 68 Ga-DOTA-ReCCMSH reached a maximum after 30 min and remained stable 2 h post-injection. A pre-targeting strategy employing D-lysine administration was effective in significantly reducing kidney retention of the tracer [87] . 18 F-FB-RMSH-1 and 18 F-FP-RMSH-1, another two metallopeptide Ac-D-Lys-ReCCMSH(Arg 11 ) probes [88, 89] , showed less favorable properties for imaging than the three probes described above.
Building upon earlier work in which 111 In-DOTA-GlyGluCycMSH was first developed to target MC1 receptors for primary and metastatic melanoma imaging [81, 90] , recent studies have determined that reduction of the ring size of 111 In-DOTA-GlyGlu-CycMSH, L-lysine co-injection, introduction of a -GG-linker, substitution of DOTA with NOTA, and 99m Tc radiolabeling via new chelators may further increase melanoma tumor uptake, while reducing nonspecific kidney and liver uptake [82, [91] [92] [93] [94] .
In addition, MC1-R-specific NAPamide analogs have been labeled with various radiometals and non-metallic radionuclides (e.g., 64 Cu, 68 Ga, 18 F, 111 In, 99m Tc, and 44 Sc), and have been widely used for the detection of melanoma or for evaluating MC1-R expression levels [95] [96] [97] [98] [99] [100] [101] . While 64 Cu-DOTA-NAPamide showed mild tumor uptake in B16/ F10-xenografted melanoma (Fig. 3a) [96] , 64 Cu-NOTAGGNle-CycMSH hex demonstrated marked uptake 2 h post-injection [93] . The latter study also revealed that the substitution of DOTA with NOTA resulted in dramatically increased melanoma uptake and decreased renal and liver uptake of 64 Cu-NOTA-GGNle-CycMSH hex .
Because of its positron emission with a high branching ratio (I = 94.27%, E mean (β+) =0.63 MeV), convenient production by the 44 Ti/ 44 Sc generator, and satisfactory physical half-life (3.97 h), the novel radiometal 44 Sc has garnered significant interest as a potential radioisotope for PET imaging [107] [108] [109] . A proof-of-concept study investigating the biological properties of the 44 Sc-labeled DOTANAPamide reported that this probe showed excellent binding to MC1-R-positive melanoma cells and tumors, slightly superior to that of 68 Ga-DOTA-NAPamide [95] . Most recently, three new MC1R-targeting peptides (CCZ01047, CCZ01048, and CCZ01056) were successfully developed, and all three 68 Ga-labeled tracers produced high-contrast PET images in B16/F10 tumors, with 68 Ga-CCZ01048 exhibiting optimal tumor uptake (Fig. 3b) . This study suggests that the introduction of a cationic piperazine (Pip) linker to Nle-CycMSH hex could improve tumor uptake and tumor-to-normal tissue contrast for the detection of melanoma [102] .
Peptide-based probes targeting the integrin family
Integrins are heterodimeric αβ transmembrane receptors that connect the extracellular matrix (ECM) to the cytoskeleton, always forming dimers by combining one of 18 α-chains with one of eight β-chains [110] . Integrin α v β 3 , and less commonly integrin α 5 β 1 , have been reported as attractive molecular targets for developing melanoma imaging probes [111] [112] [113] [114] [115] . Recent clinical studies have confirmed that 18 F-fluciclatide (formerly known as 18 F-AH111585) and 18 F-galacto-RGD are able to measure α v β 3 expression in melanoma, and that they may be useful radiotracers for assessing the response to antiangiogenic therapy in melanoma patients [116] [117] [118] [119] [120] . Nevertheless, given the low concentrations of these clinically available probes in α v β 3 -positive tumors and less than optimal PET/CT imaging quality, the need to develop sensitive and specific probes remains.
In the preclinical setting, as previously discussed [121] , a large variety of imaging strategies have been successfully employed for imaging of integrin expression in various cancer types, including melanoma. One study compared the diagnostic efficacy of 18 F-galacto-RGD with that of 68 Ga-DOTA-RGD and 111 In-DOTA-RGD, and noted that 18 F-galacto-RGD remained superior for imaging of α v β 3 expression [112] . Another group reported that although 68 Ga-Oxo-DO3A-RGD and 68 Ga-NS3-RGD demonstrated inferior characteristics compared to the existing 68 Ga-labeled RGD peptides [122] , the imaging properties of 68 Ga-NODAGA-RGD were found to be superior to those of 68 Ga-DOTA-RGD [123] , even performing comparably to 18 F-galacto-RGD (Fig. 3c) [103] . Researchers exploring ways to achieve easier and more rapid radiosynthesis have reported fusarinine-C (FSC) and SarAr to be promising Ga-68-and Zr-89-binding bifunctional chelators [114, [124] [125] [126] [127] . The most recent study by Zhai et al. noted that 68 Ga-FSC(succ-RGD) 3 exhibited improved properties compared to 68 Ga-NODAGA-RGD. The half-life of the radionuclide used ( 68 Ga, 68 min) was compatible with the pharmacokinetics of RGD peptides [128] .
When compared to DOTA, the bifunctional chelator NODAGA has gained popularity because of its significant advantages in terms of labeling chemistry [123, 129] . However, the 68 Ga labeling properties of the TRAP chelator have been found to be even better, enabling high yields and excellent reproducibility [130] [131] [132] . Notni et al. synthesized 68 Ga-avebetrin (formerly known as 68 Ga-TRAP(RGD) 3 ) and performed a comparison of biodistribution and PET data for 68 Ga-TRAP(RGD) 3 with those for 68 Ga-NODAGAc(RGDyK) and 18 F-galacto-RGD. Unlike 68 Ga-NODAGA-RGD and 18 F-galacto-RGD, 68 Ga-TRAP(RGD) 3 showed very rapid blood clearance and renal excretion, while maintaining activity concentration in tumor tissue, indicating its potential value as a next-generation α v β 3 imaging agent (Fig.  3d) [104] . After observing the excellent 68 Ga labeling properties of the TRAP-type chelator NOPO, even in the presence of high concentrations of competing metal cations (Fig. 3e) [105] , researchers further developed 68 Ga-NOPO−c(RGDfK), noting that this α v β 3 -targeting probe exhibited a higher degree of hydrophilicity than similar conjugates with other chelators, resulting in rapid and specific uptake in M21 tumor xenografts, and very rapid pharmacokinetics and renal clearance (Fig. 3f, g ) [106] . A few studies have reported on the development of α 5 β 1 -specific radiotracers [115, [133] [134] [135] . Although one candidate peptide demonstrated high specificity and affinity for α 5 β 1 in vitro, in vivo biodistribution studies showed that the radiotracer was not suitable for in vivo imaging due to its extremely and consistently high radioactivity accumulation in the blood and other major organs [136] . The reported α 5 β 1 -specific probes 18 F-PR_b and 68 Ga-NODAGAFR366 showed specific but low binding to α 5 β 1 -positive murine melanoma tumors; thus the poor tumor concentration and high kidney uptake may hinder further clinical transition of these probes [115, 137] . Notni and colleagues recently obtained 68 Gaaquibeprin by click-chemistry (CuAAC) trimerization of an α 5 β 1 pseudopeptide on the TRAP chelator, followed by automated 68 Ga labeling. Surprisingly, the trimer 68 Ga-aquibeprin possessed approximately 16-fold higher α 5 β 1 affinity than the previously reported 68 Ga-labeled pseudopeptide monomer. Although 68 Ga-aquibeprin showed lower uptake than Ga-NODAGA-RGD (left) showed more intense tumor uptake than 18 F-galacto-RGD (right) in α v β 3 -positive M21 melanoma models. d MIP images of microPET scans of M21 (filled arrows) and M21 L (unfilled arrows) human melanoma models. 68 Ga-TRAP(RGD) 3 showed high-contrast visualization of the M21 tumor. e Chemical structure of bifunctional chelator NOPO. f Relative uptake of 68 Ga-NOPO − c(RGDfK) in M21 tumor tissue and blood over time. g MIP of 68 Ga-NOPO − c(RGDfK) PET imaging in M21/M21-xenografted mice. Tumor site is marked with white arrow. Adapted and modified with permission from references [96, [102] [103] [104] [105] [106] 68 Ga-avebetrin, the probe's low background activity and high target-to-non-target contrast may offer considerable potential for elucidating the biological functions of α 5 β 1 and for detecting melanoma [138, 139] .
RGD mimetic integrin inhibitors such like cilengitide and cilengitide-like RGD peptidomimetics have also been investigated as chemical probes for the molecular imaging of angiogenesis [133, 140, 141] . In the near future, other strategies-for example, sulfonation of tyrosine moieties in RGD peptides, which can modify the hydrophilicity of RGD peptides to increase renal clearance and improve overall biodistribution [142] -can also be applied to design novel probes for mapping α v β 3 expression in melanoma. Notably, RGD can be used as an agent for surface engineering in other imaging systems to enhance melanoma targeting efficacy and therapeutic effects [143] [144] [145] [146] .
Dual-targeted peptide-based probes
In efforts to improve the in vivo pharmacokinetics and stability of the above-mentioned molecular probes, many hybrid peptides targeting both MC1R and integrin α v β 3 have been developed [147] [148] [149] [150] [151] [152] [153] . Initial synthesis and evaluation of )CCMSH showed MC1R-mediated cellular uptake of the tracer, higher tumor uptake, and prolonged tumor retention in B16/F1 melanoma-bearing mice [148] . Substitution of Gly with Ala in the hybrid peptide not only dramatically increased the MC1R binding affinity of RADLys-(Arg 11 )CCMSH compared to RGD-Lys-(Arg 11 )CCMSH (0.3 vs. 2.0 nM), but also enhanced melanoma uptake [149] . Further studies reported that Tc-RVDLys-(Arg11)CCMSH reached its highest concentration in melanoma lesions at a later time point [150] .
Flook et al. replaced the Gly with another four amino acids (Ser, Nle, Phe, and D-Phe), and noted that 99m Tc-RSD-Lys-(Arg 11 )CCMSH displayed the strongest MC1R binding affinity in vitro and exhibited optimal melanoma uptake in vivo [151] . Importantly, linkers and the charge status of the linkers between hybrid peptides may have a significant effect on the renal uptake of the tracer, as 99m Tc-RGD-(Arg 11 )-CCMSH without a linker was found to dramatically enhance the tumor-to-kidney uptake ratio [154] , and substitution of the Lys linker with the Aoc, PEG2, β Ala, or Ahx linker reduced renal uptake of the relevant probe by 58-63% at 2 h post-injection [155] [156] [157] .
Other PET/SPECT probes for melanoma imaging
In addition to radiolabeled melanin, MCR1, and integrinbased probes, here we will summarize other potential radiolabeled molecular imaging probes that have been found effective in detecting not only melanoma, but also other solid tumors. These probes can be divided into several categories, as discussed in the following sections.
Probes targeting the metabotropic glutamate 1 receptor
The metabotropic glutamate 1 (mGlu1) receptor is a G protein-coupled receptor normally expressed in the central nervous system, essential for learning and modulating the excitatory synaptic transmission in the central nervous system [158] . Recent reports have revealed that mGlu1 possesses oncogenic characteristics in melanoma by driving constitutive activation of mitogen-activated protein kinase and phosphatidylinositol-3-kinase/protein kinase B pathways [159] [160] [161] [162] [163] . Xie et al. initially developed 18 F-FITM for quantifying mGlu1 expression in the brain [164, 165] , and then successfully extended 18 F-FITM PET imaging in melanoma [67] . However, considerable uptake and slow clearance of radioactivity in the brain precluded its use in clinical applications. The same group elaborately introduced halogen atoms (chlorine, bromine, or iodine) rather than 18 F into 18 F-FITM and labeled these compounds using 11 C (half-life: 20.2 min). Of the reported compounds, the iodine analog 11 C-6 showed the highest tumor-to-brain ratio of radioactivity, and may act as a useful PET tracer for imaging mGlu1 in melanoma (Fig. 4a, b) [166] . Notably, future studies can feasibly label 11 C-6 using the isotopes of 124 I, 123 I, or 131 I for mGlu1-based theranostics of melanoma without altering their chemical structures or pharmacological profiles.
Probes targeting very late antigen-4
Within the past several years, very late antigen-4 (VLA-4; also called integrin α 4 β 1 ) has been reportedly found in cancers including melanoma [169] . LLP2A, a high-affinity peptidomimetic ligand for VLA-4, was identified from a one-bead-one-compound library and has been used for cancer imaging and therapy [170] [171] [172] . Specifically, Jiang and co-authors conjugated LLP2A with two different chelators and assessed their imaging properties in melanoma models after labeling the conjugated compounds with 64 Cu. From the biodistribution and in vivo imaging data, both 64 Cu-CB-TE1A1P-LLP2A and 64 Cu-CB-TE2A-LLP2A clearly visualized the tumors, with better contrast than that observed for 64 Cu-CB-TE1A1P-LLP2A [173] . When compared to 68 Galabeled NODAGA-LLP2A, 64 Cu-CB-TE1A1P-PEG4-LLP2A trended toward higher uptake and better tumor-tonon-target tissue ratios (Fig. 4c, d ) [167] .
Gai et al. recently designed a new probe, 64 Cu-NE3TA-PEG4-LLP2A, using the newly discovered chelator p-SCNPhPr-NE3TA, and assessed the diagnostic efficacy of the probe in melanoma xenografts. Small animal PET/CT imaging with 64 Cu-NE3TA-PEG4-LLP2A demonstrated high uptake, with a superior tumor-to-muscle ratio at 4 h post-injection [174] . In addition, a study by Beaino et al. reported that 177 Lu-DOTA-PEG 4 -LLP2A accumulated not only in primary melanoma but also in the metastatic lesions in the lung and brain, demonstrating the potential for the use of 177 Lu-DOTA-PEG 4 -LLP2A as an alternative treatment strategy for metastatic VLA-4 expressing melanoma [175] .
Probes targeting indoleamine 2,3-dioxygenase (IDO)
In recent years, advances in immunotherapy have dramatically altered the landscape of melanoma treatment [176] . However, recent findings reveal that indoleamine 2,3-dioxygenase (IDO) can be triggered by innate responses during tumorigenesis, and also by attempted T-cell activation (either spontaneous or due to immunotherapy), contributing to immunosuppression and leading to immune tolerance. IDO inhibitors thus represent a novel class of immunomodulators with broad application in the treatment of advanced human cancer [177, 178] . In an effort to map tryptophan (Trp, a substrate of IDO) metabolism [179, 180] , one group found that the radionuclide-labeled IDO inhibitor 5-[18F]F-AMT may hold great potential for melanoma imaging [168] . Using a B16/F10 melanoma model, the authors found that tumors were clearly visible, and this probe may have been excreted through the urinary system, as the kidneys showed initial high uptake (Fig. 4e, f) . These preliminary results imply potential use of this series of probes, as the superior tumor-to-background ratio may precisely delineate primary and metastatic melanomas, although the probes are not melanoma-specific and are concentrated in other tumor types, such as breast cancer, as well [179] .
Probes targeting the immune checkpoints
As the field of cancer immunotherapy has undergone tremendous growth over the past decade, noninvasive molecular imaging strategies have been used to map the biodistribution of immune checkpoint molecules, monitor the efficacy and potential toxicities of the treatments, and identify patients who will potentially benefit from immunotherapy [181] . Studies have shown that PET may be used for the noninvasive imaging of PD-1/PD-L1 expression in melanoma and for determining the extent of tumor infiltration of lymphocytes [182, 183] . Nedrow et al. recently developed a PD-L1-targeted imaging agent, 111 In-DTPA-anti-PD-L1-BC, which demonstrated the greatest tumor uptake at 24 h post-injection, with a tumor-to-muscle ratio of 4.6, in B16/F10 tumor-bearing mice. Whole-body SPECT images showed that the tumor, as well as the spleen and liver, was clearly defined at the later time points [184] . [166] [167] [168] Probes targeting the human copper transporter 1 (CTR1)
Human copper transporter 1 (CTR1), a 190-amino acid protein of 28 kDa with three transmembrane domains [185] , has been proven to be over-expressed in melanoma. The utility of 64 Cu 2+ ions as PET probes is premised on the fact that Cu is an essential element that plays an important role in cell proliferation and angiogenesis [186] , and thus several studies have investigated copper radionuclidebased imaging of cancers [187, 188] . Although 64 CuCl 2 was reported to be a promising novel PET probe for imaging of melanoma [189] , there have been reports that CTR1 is the specific influx copper transporter for 64 Cu(II) by in vivo PET imaging and biodistribution [190] . However, additional studies are still needed to evaluate the feasibility of 64 Cu(I) as a PET imaging radiotracer for melanoma detection.
Antibody-based imaging probes
In light of recent developments in antibody engineering, and given the in vivo stability and high specificity of these probes, radiolabeled monoclonal antibodies (mAb), antibody fragments, and engineered antibody derivatives are increasingly used as agents in diagnosis and treatment [191, 192] . Twenty years have passed since initial attempts in melanoma detection using radiolabeled antibodies [193, 194] . In addition to melanin-specific antibodies [195] [196] [197] [198] [199] , GD2 is highly expressed on the cell surface of a broad spectrum of human cancers, including melanoma, and has been successfully exploited as a molecular target for therapy and molecular imaging [200] . Voss et al. successfully developed a SarArconjugated, 64 Cu-labeled anti-GD2 antibody construct, 64 Cu-SarAr-GD2 mAb ch14.18, and performed in vivo studies using GD2-expressing melanoma xenografts. Their results showed that about 20.5% of the injected dose accumulated in the M21 melanoma tumors [201] , and further studies from the same group confirmed this finding [202, 203] . These preliminary results may indicate the feasibility of the 64 Cu-SarAr antibody as a platform for imaging of melanoma.
Probes targeting CXCR4
C-X-C chemokine receptor type 4 (CXCR4, also called fusin, CD184) is a seven-transmembrane G-coupled receptor belonging to the chemokine receptor family, and has been found to be over-expressed in various human cancers including lymphoma, neuroendocrine tumors, malignant glioma, lung cancer, and multiple myeloma [204] [205] [206] [207] [208] . CXCR4-based imaging was also recently investigated for detection of melanoma [209] . In a clinical trial dedicated to estimate CXCR4 overexpression by using the novel CXCR4-specific probe 68 Ga-pentixafor, Vag et al. included 21 patients (two of them melanoma patients) and demonstrated the feasibility of 68 Ga-pentixafor for PET imaging of solid malignancies, although the detectability of solid cancers by 68 Ga-pentixafor seemed to be lower than with 18 F-FDG PET [210] .
Image-guided therapy for melanoma
In addition to melanoma imaging, molecular imaging-guided therapy for treatment of melanoma has long been a hot topic in the field, as recently reviewed by Norain et al. [211] . Radionuclide-based therapy can be realized through radiolabeled antibodies, peptides, or small molecules.
Radiolabeled antibodies and peptides
Lutetium-177 ( 177 Lu) is a low-energy β-emitter (497 keV, 90%) with a half-life of 6.7 days and maximum tissue penetration of 1.6 mm. 177 Lu also emits γ-rays (113 and 208 keV, 6% and 11%) suitable for image-guided drug delivery using SPECT. Antibodies and peptides radiolabeled with 177 Lu are attractive therapeutic agents due to localized deposition of beta decay energy and a radioactive half-life that matches the in vivo pharmacokinetics of targeting antibodies quite well [212] [213] [214] . Vascular endothelial growth factor (VEGF) has been studied extensively as a protein with a major role in physiological and pathological angiogenesis [215, 216] . A recent work reported that 177 Lu-DOTA-bevacizumab (a recombinant humanized monoclonal antibody that binds to all VEGF isoforms) had shown preliminary potential as a novel radioimmunotherapy and molecular imaging agent for melanoma [217] .
Building upon the success of the lactam bridge-cyclized α-MSH peptides for melanoma imaging discussed above, Guo et al. assessed the image-guided therapeutic effect of 177 Lu-DOTAGGNle-CycMSH hex in B16/F1 melanomabearing mice, and found high melanoma uptake and fast urinary clearance of the probe, underscoring its potential as a theranostic agent for metastatic melanoma [218] . 188 Re, a high-energy β-emitter (maximum energy: 2.12 MeV), has a considerable range (several millimeters) in tissue and a relatively short half-life of 16.9 h. 188 Re-labeled melanin-specific antibodies for melanoma therapy have also been studied. 188 Re-labeled 6D2 [197] , a melanin-binding IgM antibody, has been proven effective in treating pigmented human melanoma tumors and in augmenting the efficacy of the chemotherapeutic agent dacarbazine (DTIC) [198] . Notably, through the separate administration of the targeting vector and radioisotope, in vivo pre-targeting appears to be a promising approach for enhancing the tumor-targeting properties of radiolabeled antibodies, while simultaneously avoiding their pharmacokinetic limitations. Pictorial abstract showing PET and SPECT imaging probes for malignant melanoma. Molecular targets discussed above can be divided into two groups: melanoma-specific targets, indicated by grayscale models, and melanomanonspecific targets, indicated by color models 219, 220] . ICF01012 was labeled with 123 I for melanoma imaging and with 131 I for melanoma treatment (Fig. 5a, b) . The preliminary results not only showed a correlation between radiotracer uptake and melanin content, but also demonstrated significantly reduced tumor growth and prolonged the median survival of the melanoma-bearing mice after administration of 131 I-ICF01012 [221] . The combination of 131 I-ICF01012 and coDbait, a DNA repair inhibitor, was able to overcome melanoma radioresistance and increase the efficacy of targeted radionuclide therapy (TRT), with no increase in side effects [223] . In a clinical study which enrolled 26 patients with metastatic melanoma, Mier et al. reported post-treatment survival of over 2 years in three of five patients who received higher doses of treatment by administration of the melanin-binding 131 I-BA52 (Fig. 5c, d ). In contrast, the mean overall survival of the untreated and insufficiently dosed patients was approximately 3 months [222] . Interestingly, some studies have also reported on the development of iodinated and fluorinated radiotracers targeting melanin, offering the potential for both diagnosis (SPECT and PET imaging) and therapy (iodine-131) [224] [225] [226] .
Radiolabeled small molecules

Conclusions and future perspectives
As summarized in Fig. 6 , in this review we have provided an informative survey of the recent progress in radiolabeled molecular imaging probes for imaging of various molecular targets or processes in malignant melanoma. While melanin, MCR1, and integrins represent the traditional and most common targets for melanoma detection and therapy, tumor metabolism and immune microenvironment-based molecular imaging probes have also appeared in recent years. In an era of precision medicine, concerted efforts toward developing radiolabeled molecular probes for mapping and treatment of melanoma are extremely important, and the need for new probes with optimal imaging properties remains high.
Looking to the future, we would like to put forward three proposals. First, with the rapid development of molecular imaging, novel molecular imaging probes with high sensitivity and specificity enable us to characterize melanoma at the molecular level. These new probes will provide a powerful platform for early diagnosis of both primary and metastatic melanoma; monitoring of therapeutic response; accurate staging and restaging of melanoma; stratification of patients for antiangiogenesis therapy, immunotherapy, and radionuclide therapy; and facilitation of new drug discovery for melanoma treatment. Second, melanin, MC1R, and integrins have been extensively investigated as targets for selective imaging and therapeutic agents against melanoma, and though the potential for many of these probes can be effectively demonstrated in preclinical settings, very few could actually be translated to the clinic. Future studies should be dedicated to advancing the clinical transition of some of the most promising of these probes. Third, the use of humanized mice rather than cultured cell lines and mouse xenografts [227] could examine the probes in the context of the human immune system and tumor microenvironment, and accelerate clinical transition.
To conclude, malignant melanoma represents a serious threat to public health, and is a deadly disease when diagnosed at a late stage. With the elucidation of many important oncogenic signaling pathways and biomarkers involved in malignant melanoma pathogenesis, we believe that PET and SPECT imaging, as well as image-guided therapy, will undoubtedly provide better visualization and management of malignant melanoma in the future.
